Literature DB >> 8607449

Primary body cavity-based AIDS-related lymphomas.

M Q Ansari1, D B Dawson, R Nador, C Rutherford, N R Schneider, M J Latimer, L Picker, D M Knowles, R W McKenna.   

Abstract

Five patients with advanced AIDS developed a unique type of high grade primary body cavity-based non-Hodgkin's lymphoma (NHL). The lymphomas were exclusively in serous effusions with no detectable mass disease in the body cavities and no lymphadenopathy or organomegaly. All of the lymphomas exhibited virtually identical morphology, which could not be precisely classified, but appeared to bridge features of large cell immunoblastic and anaplastic large cell lymphomas. Immunophenotypically the lymphoma cells lacked expression of any B- or T-lymphocyte antigens, but expressed CD45 and the activation antigens CD30, CD38, CD71, and HLA-DR. Clonally rearranged immunoglobulin heavy chain and kappa light chain genes were identified by Southern blot analysis. Molecular studies also revealed Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) genomes and germline configuration of the c-myc protooncogene. In two cases studied cytogenetically, the lymphoma cells manifested complex chromosome abnormalities. These lymphomas are clinically and biologically unique and found predominantly in patients with advanced AIDS, in many cases with pre-existing Kaposi's sarcoma.

Entities:  

Mesh:

Year:  1996        PMID: 8607449     DOI: 10.1093/ajcp/105.2.221

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  26 in total

1.  Lymphoid disorders associated with HHV-8/KSHV infection: facts and contentions.

Authors:  G Gaidano; E Castaños-Velez; P Biberfeld
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

Review 2.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

3.  Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus.

Authors:  Jong-Ho Won; Seung-Hyo Han; Sang-Byung Bae; Chan-Kyu Kim; Nam-Su Lee; Kyu-Taeg Lee; Sung-Kyu Park; Dae-Sik Hong; Dong-Wha Lee; Hee-Sook Park
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

4.  Expression profile of human herpesvirus 8 (HHV-8) in pyothorax associated lymphoma and in effusion lymphoma.

Authors:  M O'Donovan; I Silva; V Uhlmann; N Bermingham; K Luttich; C Martin; O Sheils; A Killalea; C Kenny; S Pileri; J J O'Leary
Journal:  Mol Pathol       Date:  2001-04

Review 5.  Kaposi's sarcoma associated herpes virus (KSHV/HHV 8): epidemiology, molecular biology and tissue distribution.

Authors:  J J O'Leary; M M Kennedy; J O McGee
Journal:  Mol Pathol       Date:  1997-02

6.  In situ polymerase chain reaction-based localization studies support role of human herpesvirus-8 as the cause of two AIDS-related neoplasms: Kaposi's sarcoma and body cavity lymphoma.

Authors:  K E Foreman; P E Bacon; E D Hsi; B J Nickoloff
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

7.  Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma.

Authors:  R Wagener; L B Alexandrov; M Montesinos-Rongen; M Schlesner; A Haake; H G Drexler; J Richter; G R Bignell; U McDermott; R Siebert
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

8.  AIDS and non AIDS-related malignant lymphoma in Tanzania.

Authors:  Ephata E Kaaya; Esmeralda Castaños-Velez; Marianne Ekman; Amos Mwakigonja; Primo Carneiro; Leonard Lema; James Kitinya; Anika Linde; Peter Biberfeld
Journal:  Afr Health Sci       Date:  2006-06       Impact factor: 0.927

9.  Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells.

Authors:  Lei Chen; Michael Lagunoff
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 10.  Primary effusional lymphoma: A new non-Hodgkin s lymphoma entity.

Authors:  A Matolcsy
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.